Related references
Note: Only part of the references are listed.Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson's Disease
Venkatesh Atul Bhattaram et al.
AAPS JOURNAL (2009)
Double-Blind Trial of Levodopa/Carbidopa/Entacapone Versus Levodopa/Carbidopa in Early Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2009)
Disease-modification trials in Parkinson disease: Target populations, endpoints and study design
Olivier Rascol
NEUROLOGY (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight
J. C. Sharma et al.
EUROPEAN JOURNAL OF NEUROLOGY (2008)
Progress in neuroprotection in Parkinson's disease
A. H. V. Schapira
EUROPEAN JOURNAL OF NEUROLOGY (2008)
An expert opinion on safinamide in Parkinson's disease
Marco Onofrj et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD
R. Katzenschlager et al.
NEUROLOGY (2008)
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
Robert A. Hauser et al.
MOVEMENT DISORDERS (2007)
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole
Nir Giladi et al.
MOVEMENT DISORDERS (2007)
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease
Hubert H. Fernandez et al.
PHARMACOTHERAPY (2007)
Treatment options in the modern management of Parkinson Disease
Anthony H. V. Schapira
ARCHIVES OF NEUROLOGY (2007)
Impact of pramipexole on the onset of levodopa-related dyskinesias
Radu Constantinescu et al.
MOVEMENT DISORDERS (2007)
Transdermal rotigotine - Double-blind, placebo-controlled trial in Parkinson disease
Joseph Jankovic et al.
ARCHIVES OF NEUROLOGY (2007)
A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis
D. Grosset et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
R. L. Watts et al.
NEUROLOGY (2007)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation -: A mass balance trial
Willi Cawello et al.
CLINICAL PHARMACOKINETICS (2007)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society- European Section. Part I: Early (uncomplicated) Parkinson's disease
M. Horstink et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Dopamine agonists and cardiac valvulopathy in Parkinson disease - A case-control study
Mitsutoshi Yamamoto et al.
NEUROLOGY (2006)
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Selegiline slows the progression of the symptoms of Parkinson disease
S Pålhagen et al.
NEUROLOGY (2006)
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
AHV Schapira et al.
ANNALS OF NEUROLOGY (2006)
Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade)
Jagdish C. Sharma et al.
PARKINSONISM & RELATED DISORDERS (2006)
Epidemiology of Parkinson's disease
Lonneke M. L. de Lau et al.
LANCET NEUROLOGY (2006)
Does levodopa slow or hasten the rate of progression of Parkinson's disease?
S Fahn
JOURNAL OF NEUROLOGY (2005)
Diagnosis and initial management of Parkinson's disease
JG Nutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Sudden uncontrollable somnolence and medication use in Parkinson disease
J Avorn et al.
ARCHIVES OF NEUROLOGY (2005)
A novel dopamine agonist for the transdermal treatment of Parkinson's disease
P Jenner
NEUROLOGY (2005)
Entacapone in the treatment of Parkinson's disease
A Schrag
LANCET NEUROLOGY (2005)
Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
CG Goetz et al.
MOVEMENT DISORDERS (2005)
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates
LA Smith et al.
MOVEMENT DISORDERS (2005)
The role of radiotracer imaging in Parkinson disease
B Ravina et al.
NEUROLOGY (2005)
Neuroprotection in Parkinson disease - Mysteries, myths, and misconceptions
AHV Schapira et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
NJ Ives et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Improvement of motor function in early Parkinson disease by safinamide
F Stocchi et al.
NEUROLOGY (2004)
A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease
MBH Youdim et al.
NEUROLOGY (2004)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
AL Whone et al.
ANNALS OF NEUROLOGY (2003)
Incidence of Parkinson's disease: Variation by age, gender, and Race/Ethnicity
SK Van Den Eeden et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Genomic medicine: Alzheimer's disease and Parkinson's disease
RL Nussbaum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Slowing Parkinson's disease progression - Recent dopamine agonist trials
JE Ahlskog
NEUROLOGY (2003)
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
I Shoulson et al.
ANNALS OF NEUROLOGY (2002)
Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review - Report of the quality standards subcommittee of the American Academy of Neurology
JM Miyasaki et al.
NEUROLOGY (2002)
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease
D Deleu et al.
CLINICAL PHARMACOKINETICS (2002)
Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease
LV Metman et al.
CLINICAL NEUROPHARMACOLOGY (2001)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
MBH Youdim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
WD Le et al.
DRUGS & AGING (2001)
Ropinirole - A review of its use in the management of Parkinson's disease
AJ Matheson et al.
DRUGS (2000)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Pharmacotherapy for advanced Parkinson's disease
M Stacy
PHARMACOTHERAPY (2000)
Share Paper
